Dicot Pharma outlines Phase 2b trial design for ED drug candidate LIB-01 at Oct. 13 investor webcast

• Dicot Pharma scheduled a webcast investor presentation for Oct. 13 to recap clinical findings on LIB-01 from an Oct. 8–11 medical meeting.
• Results were set to be presented first at the SMSNA conference in Orlando, then repeated online because the event cannot be followed remotely.
• Abstracts described durable pro-erectile effects linked to gene-level modulation, supporting a differentiated mechanism versus existing erectile dysfunction drugs.
• Clinical updates pointed to meaningful, long-lasting improvements in erectile function, with effects described as persisting for weeks.
• Materials also outlined a Phase 2b trial design tailored to LIB-01’s durable pharmacodynamic profile, framing the next development step.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dicot Pharma AB published the original content used to generate this news brief on October 07, 2026, and is solely responsible for the information contained therein.